DOCSLIB.ORG

LEVOSULPIRIDE ARISTO 25 Mg, 50 Mg, 100 Mg Tablets

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
LEVOSULPIRIDE ARISTO 25 Mg, 50 Mg, 100 Mg Tablets CMDh/223/2005 February 2014 Public Assessment Report Scientific discussion LEVOSULPIRIDE ARISTO 25 mg, 50 mg, 100 mg tablets Aristo Pharma GmbH Wallenroder Straβe 8-10 13435 Berlino Germania IT/H/534/001-003/DC Date: 15/06/2020 This module reflects the scientific discussion for the approval of Levosulpiride Aristo. The procedure was finalised at 5 June 2019. For information on changes after this date please refer to the module ‘Update’. I. INTRODUCTION Based on the review of the quality, safety and efficacy data, the Member States have granted a marketing authorisation for Levosulpiride Aristo, 25 mg, 50 mg and 100 mg tablet, from Aristo Pharma GmbH. Levosulpiride Aristo 25 mg is indicated for: • Short-term treatment of dyspeptic syndrome (anorexia, bloating, a feeling of epigastric tenderness, postprandial headache, heartburn, belching, diarrhoea, constipation) from delayed gastric emptying related to organic factors (diabetic gastroparesis, cancer, etc.) and / or functional factors (visceral somatisation in anxious subjects -depressants) in patients who failed to respond to other therapy. • Symptomatic short-term treatment of nausea and vomiting (induced by anticancer drugs) after failure of first-line therapy. • Symptomatic short-term treatment of dizziness, tinnitus, hearing loss and nausea associated with Meniere’s syndrome. Levosulpiride Aristo 50 mg and 100 mg is indicated for: • Somatic symptom disorders. • Treatment of chronic schizophrenia with negative symptoms. A comprehensive description of the indications and posology is given in the SmPC. The active substance levosulpiride belongs to the pharmacotherapeutic group of psycholeptics, antipsychotics, ATC code: N05AL07. Levosulpride blocks the presynaptic dopaminergic D2 receptors. Like its parent compound (sulpiride), levosulpiride shows antagonism at D3 and D2 receptors present presynaptically as well as postsynaptically. The preferential binding of the presynaptic dopamine receptors decreases the synthesis and release of dopamine at low doses whereas it causes postsynaptic D2 receptor antagonism at higher dose. This receptor profile together with its limbic selectivity explains its effectiveness of levosulpiride in the management of negative symptoms of schizophrenia. The antagonism of central D2 receptors may lead to both therapeutic (e.g. anti-emetic effect due to D2 receptor blockade in the area postrema) and adverse (including hyperprolactinaemia and extrapyramidal dystonic reactions) effects. Levosulpiride has a stimulant effect on 5-HT4 receptors and to a lesser extent on 5-HT3 receptors. Its action on 5-HT receptors is thought to account for the ability to stimulate gastric and small bowel motility and to accelerate gastric emptying in patients suffering from functional dyspepsia and diabetic gastroparesis. Levosulpiride is more effective than domperidone, metoclopramide and at least as effective as cisapride. Levosulpiride has stimulating activity at low doses and sedative effects only at very high doses, due to the blockade of central pre-synaptic autoreceptors and post-synaptic D2 receptors, respectively (this is why it is placed apart as a mainly atypical neuroleptic agent). This is probably the reason why levosulpiride has only a low potential to induce extrapyramidal side-effects at the doses used in gastroenterology. The marketing authorisation has been granted pursuant to Article 10.1 generic application of Directive 2001/83/EC as amended. Essential similarity is claimed to Levopraid tablets produced by Teopharma srl Italy, registered since 20 November 1985. The application for the Marketing Authorization was a Decentralised Procedure with Italy acting as the Reference Member State (RMS) and Spain as the only Concerned Member State (CMS). The RMS has been assured that acceptable standards of GMP are in place for this product type at all sites responsible for the manufacture and assembly of the product. Regarding the statement on GMP for the active substance a suitable declaration is provided from the manufacturer responsible for manufacture of the finished product and batch release situated in the EU. PAR Scientific discussion IT/H/534/001-003/DC Levosulpiride Aristo 25 mg, 50 mg, 100 mg tablets In the bioequivalence study report it has been stated that clinical and analytical parts were carried out in accordance with the current GCP/GLP. II. QUALITY ASPECTS II.1 Introduction Levosulpiride Aristo is formulated as tablets containing 25 mg, 50 mg and 100 mg of levosulpiride and packed in blister of PVC/PVDC sealed with Aluminium foil. The 25 mg tablets are white, round, convex tablet, with 6 mm diameter, imprinted with “MC” on one side. The 50 mg tablet are white, round, convex tablet, with 8 mm diameter imprinted with “50” on one side. The 100 mg tablets are white, round, convex tablet, with 10.3 mm diameter. II.2 2.2Drug Substance The active substance used in the manufacture of the applied finished product Levosulpiride tablets is levosulpiride (Sulpiride S-enantiomer) that is not described in the European Pharmacopoea. An ASMF procedure was followed for levosulpiride. INN: Levosulpiride IUPAC Name: (S)-N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxy-5-sulphamoylbenzamide Other Chemical Name: 5-aminosulphonyl-N-(1-ethyl-pyrrolidin-2-ylmethyl)-2-methoxybenzamide CAS Registry Number: 23672-07-3 Structure: Chirality: Levosulpiride is the S-enantiomer of sulpiride. A chiral center is present in sulpiride molecular structure, but the starting material and the route of synthesis used allow the formation of the S-enantiomer only (see structural formula above (S-enantiomer). Relative molecular mass: 341.4 Molecular formula: C15H23N3O4S Appearance: white crystalline powder Melting Range: 184 – 189 °C Solubility: practically insoluble in water, sparingly soluble in methanol, slightly soluble in alcohol and in methylene chloride; it dissolves in dilute solutions of mineral acids and alkali hydroxides. pKa: measured in methanol:water (1:1) is 8.5. Partition coefficient: observed log P for Sulpiride is 0.42 Polymorphism: the X-ray analysis was performed on several batches and no differences are visible in the obtained diffractograms that are also perfectly super imposable, demonstrating that no polymorphism is present in Levosulpiride (Sulpiride S-enantiomer) production batches manufactured by the proposed manufacturer. So far no other crystalline forms have been described in the literature. PAR Scientific discussion IT/H/534/001-003/DC Levosulpiride Aristo 25 mg, 50 mg, 100 mg tablets The quality of the active substance has been adequately demonstrated and the stability proven. A re- test period of five years was accepted. II.3 Medicinal Product The medicinal product is supplied as tablets containing 25 mg, 50 mg and 100 mg of levosulpiride. The excipients are microcrystalline cellulose, lactose monohydrate, sodium starch glycolate, magnesium stearate. Pharmaceutical development The excipients and packaging are usual for this type of dosage form. The development of the product has been described, the choice of excipients is justified and their functions explained. A Bioequivalence study with the higher strength of 100 mg has been performed and a biowaiver has been requested for the other dosage strengths based on the justification that the pharmacokinetics of the active substance is linear in the whole range of strengths, the qualitative composition of the different strengths is the same, the quantitative composition is fully proportional across strengths and the products are manufactured through the same manufacturing process. Comparative dissolution profiles between the test product and the reference product Levopraid (including the batches of 100 mg used in the Bioequivalence study) and between the 100 mg tablet biobatch of the test product and the batches of the lower strengths have been provided and demonstrated to be similar. The active substance exhibits high solubility in the proposed dissolution medium, HCl 0.1N, as well as in the pH 4.5 and pH 6.8 medium, since the percentage dissolved is higher than 85% at 15 minutes (very rapidly dissolving scenario). The pharmaceutical development of the product has been adequately performed. Manufacturing Process The proposed manufacturing process is standard and consists of blending of the levosulpiride powder with the excipients and direction compression of the final powder blend. Sufficient details on equipment and operational parameters have been provided. Validation protocols has been provided. Product specifications The product specification are adequate for the dosage form. The potential contamination of the elemental impurities in accordance to the ICH Q3D guideline has been adequately investigated. The analytical methods have been adequately described and validated. Batch analytical data have been provided demonstrating compliance with the release specification. Stability The stability studies have been conducted in accordance to ICH storage conditions and cover the proposed shelf-life of 36 months with no special storage conditions. II.4 Discussion on chemical, pharmaceutical and biological aspects The quality characteristics of Levosulpiride Aristo tablets 25 mg, 50 mg and 100 mg are well defined and controlled. The specifications and batch analytical results indicate consistency from batch to batch. There are no outstanding quality issues that would have a negative impact on the benefit/risk. III. NON-CLINICAL ASPECTS This product is a generic formulation of Levopraid, which is available on the
Load more

Recommended publications
  • The SULPYCO Method Using Sulpiride Integrated with an Atypical Adjuvant Therapy for Treating Depressive Syndrome: an Observational Study Amgad M
    oepidem ac io m lo r g a y Rabie, Adv Pharmacoepidem Drug Safety 2013, 2:1 h & P Advances in Pharmacoepidemiology & D n i DOI: 10.4172/2167-1052.1000126 r u s g e c ISSN: 2167-1052 S n a a f v e t d y A Drug Safety Research Article Open Access The SULPYCO Method Using Sulpiride Integrated with an Atypical Adjuvant Therapy for Treating Depressive Syndrome: An Observational Study Amgad M. Rabie* Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Mansoura University, Mansoura, Dakahlia Governorate, Egypt Abstract In this observational study, we studied the effects of a new drug combination on depression. Patients were analyzed before and after antidepressant treatment using the Hamilton rating scale for depression (HAMD). One group of patients was treated with the new integrated medicine consisting of two separate subcutaneous injections of a low dose (20 mg) of sulpiride and a 2.2 ml complex homeopathic solution based on the Krebs cycle elements; each injection was administered once daily. Another group of patients was treated with conventional therapy of 20 mg sulpiride only. The third group was treated with only the homeopathic solution. The differences in the HAMD scores were evaluated before and after 3 months of treatment in these three groups of patients. The HAMD score showed a statistically significant decrease in the group treated with combined sulpiride and homeopathy. This observation suggests that a low parenteral dose (20 mg) of sulpiride, when administered subcutaneously with a complex homeopathic remedy, may give better therapeutic results for mild and moderate depression than either sulpiride or complex homeopathy alone.
    [Show full text]
  • Pharmaceuticals and Medical Devices Safety Information No
    Pharmaceuticals and Medical Devices Safety Information No. 258 June 2009 Table of Contents 1. Selective serotonin reuptake inhibitors (SSRIs) and aggression ······································································································································ 3 2. Important Safety Information ······································································· 10 . .1. Isoflurane ························································································· 10 3. Revision of PRECAUTIONS (No. 206) Olmesartan medoxomil (and 3 others)··························································· 15 4. List of products subject to Early Post-marketing Phase Vigilance.....................................................17 Reference 1. Project for promoting safe use of drugs.............................................20 Reference 2. Manuals for Management of Individual Serious Adverse Drug Reactions..................................................................................21 Reference 3. Extension of cooperating hospitals in the project for “Japan Drug Information Institute in Pregnancy” ..............25 This Pharmaceuticals and Medical Devices Safety Information (PMDSI) is issued based on safety information collected by the Ministry of Health, Labour and Welfare. It is intended to facilitate safer use of pharmaceuticals and medical devices by healthcare providers. PMDSI is available on the Pharmaceuticals and Medical Devices Agency website (http://www.pmda.go.jp/english/index.html) and on the
    [Show full text]
  • Pharmacology and Toxicology of Amphetamine and Related Designer Drugs
    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.
    [Show full text]
  • Effect of Chronic Administration of Antidepressants on Duration of Immobility in Rats Forced to Swim
    Effect of Chronic Administration of Antidepressants on Duration of Immobility in Rats Forced to Swim Kazuaki KAWASHIMA, Hiroaki ARAKI and Hironaka AIHARA Department of Pharmacology, Research Center, Taisho Pharamceutical Co., Ltd., Yoshino-cho 1-403, Ohmiya, Saitama 330, Japan Accepted October 14, 1985 Abstract-Chronic administration of imipramine and desipramine significantly reduced the duration of immobility in rats forced to swim in comparison with acute administration. However, amitriptyline did not potentiate the reductive effect of chronic administration. Chlorimipramine, a selective serotonin uptake inhibitor, did not affect the duration of immobility in both the acute and chronic adminis tration. On the other hand, the chronic administration of chlorpromazine, haloperidol and diazepam enhanced the duration of immobility, whereas their acute administration had no effect on it. Sulpiride reduced and enhanced the duration of immobility by the acute and chronic administration, respectively. The present results suggest that the chronic administration of drugs to rats in a forced swimming test can clarify the characteristics of the psychotropic drugs. The forced swimming test in rats and mice illnesses. So, we were very interested in is a useful model for the screening of anti investigating the effects of sulpiride in rats depressants. Porsolt et al. described that forced to swim, particularly, with regard to animals forced to swim in a restricted space the difference between its acute and chronic ceased to make attempts to escape and be administration. The present study was came immobile. This immobility was reduced performed to investigate the effects of the and extended by the acute administration of chronic administration of antidepressants, typical and atypical antidepressants and neuroleptics including sulpiride, and anxioly neuroleptics and anxiolytics, respectively (1 tics on the duration of immobility in rats 3).
    [Show full text]
  • Severe Extrapyramidal Symptoms Due to Sulpiride and Fluoxetine Combination in a Case of OCD*
    B. Kaya, M. Güzelipek, M. E. Özcan Severe Extrapyramidal Symptoms Due to Sulpiride and Fluoxetine Combination in a Case of OCD* Burhanettin Kaya M.D.1, Mehmet Güzelipek M.D.2, M. Erkan Özcan M.D.1 ABSTRACT: ÖZET: SEVERE EXTRAPYRAMIDAL SYMPTOMS DUE TO SULPIRIDE SÜLP‹R‹D VE FLUOKSET‹N’‹N B‹RL‹KTE KULLANIMINA BA⁄LI AND FLUOXETINE COMBINATION IN A CASE OF OCD OLARAK fi‹DDETL‹ EKSTRAP‹RAM‹DAL YAN ETK‹ ORTAYA ÇIKAN B‹R OKB OLGUSU Sulpiride is an antipsychotic agent which has an antidepressant effect in low doses. The combination of antipsychotics in lower Düflük dozlarda kullan›lan sülpiridin antidepresan etkinlik gös- dosages with antidepressants in obsessive-compulsive disorder terdi¤i bilinmektedir. Obsesif kompulsif bozuklu¤un (OKB) (OCD) patients has also been reported to be useful. The case tedavisinde düflük dozlarda antidepresan ilaçlarla birlikte kul- reported was a 53 years old female patient with OCD and major lan›labilmektedir. DSM-V’e göre OKB ve major depresyon tan›s› depression according to the DSM-IV diagnostic criteria. OCD konan 53 yafl›nda bayan hasta. 6 y›ld›r süren OKB’u, 6 ayd›r diagnosis was present for six years and she had been süren depresyonu var. Dirençli OKB olarak kabul edilen ve has- depressied for the last six months. She was accepted as having taneye yat›r›lan hastaya 20 mg/gün fluoksetin baflland›. 1 hafta resistant OCD according to the patient’s history. After she was sonra doz 40 mg’a yükseltildi ve 200 mg sülpirid eklendi. hospitalized, the treatment began with fluoksetin 20 mg/day.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,255,329 B1 Maj (45) Date of Patent: *Jul
    USOO6255329B1 (12) United States Patent (10) Patent No.: US 6,255,329 B1 Maj (45) Date of Patent: *Jul. 3, 2001 (54) COMBINED USE OF PRAMIPEXOLE AND Carter et al Eur. J. Pharmacol. 200(1):65–72 Pra & SERTRALINE FOR THE TREATMENT OF Sulpiride, 1991.* DEPRESSION Borsini et al Psychopharmacology (Berlin) 97(2):183-188 Forced Swimming Test Discovers Antidepressant Activity, (75) Inventor: Jerzy Maj, Kracau (PL) 1989.* Piercey et all Clinical Neuropharmacology 18 Suppl. 1 (73) Assignee: Boehringer Ingelheim Pharma KG, 534–542 Pra & Quinpirole, 1995.* Ingelheim (DE) Willner Psycyhopharmacology 83(1):1-16 Learned Help lessness Test for Antidepress, 1984.* (*) Notice: This patent issued on a continued pros Borsini et al Psychopharmacology 94(2): 147-160 FST in ecution application filed under 37 CFR Rats, not Mice Detects Antidepressants, 1988.* 1.53(d), and is subject to the twenty year Skrebuhhova et al Methods & Findings Exp. Clin. Pharma patent term provisions of 35 U.S.C. col. 21(3):173–178 FST 4, 1999.* 154(a)(2). Harkin et al Eur. J. Pharmacol. 364 2–3 123–132 Sertraline FST, Jan. 1999.* Subject to any disclaimer, the term of this J. Maj, Z. Rogoz, G. Skuza & K. Kolodziejczyk; “Antide patent is extended or adjusted under 35 pressant Effects Of Pramipexole, A Novel Dopamine Recep U.S.C. 154(b) by 0 days. tor Agonist'; Journal of Neural Transmission; Aug. 6, 1997; pp. 525-533; vol. 104; Pub. Springer-Verlag, Austria. (21) Appl. No.: 09/348,591 J. Maj, Z. Rogoz, G. Skuza & K. Kolodziejczyk; “Prami pexole Given Repeatedly Increases Responsiveness Of (22) Filed: Jul.
    [Show full text]
  • Use of Prescribed Psychotropics During Pregnancy: a Systematic Review of Pregnancy, Neonatal, and Childhood Outcomes
    brain sciences Review Use of Prescribed Psychotropics during Pregnancy: A Systematic Review of Pregnancy, Neonatal, and Childhood Outcomes Catherine E. Creeley * and Lisa K. Denton Department of Psychology, State University of New York at Fredonia, Fredonia, NY 14063 USA; [email protected] * Correspondence: [email protected]; Tel.: +1-716-673-3890 Received: 19 July 2019; Accepted: 9 September 2019; Published: 14 September 2019 Abstract: This paper reviews the findings from preclinical animal and human clinical research investigating maternal/fetal, neonatal, and child neurodevelopmental outcomes following prenatal exposure to psychotropic drugs. Evidence for the risks associated with prenatal exposure was examined, including teratogenicity, neurodevelopmental effects, neonatal toxicity, and long-term neurobehavioral consequences (i.e., behavioral teratogenicity). We conducted a comprehensive review of the recent results and conclusions of original research and reviews, respectively, which have investigated the short- and long-term impact of drugs commonly prescribed to pregnant women for psychological disorders, including mood, anxiety, and sleep disorders. Because mental illness in the mother is not a benign event, and may itself pose significant risks to both mother and child, simply discontinuing or avoiding medication use during pregnancy may not be possible. Therefore, prenatal exposure to psychotropic drugs is a major public health concern. Decisions regarding drug choice, dose, and duration should be made carefully, by balancing severity, chronicity, and co-morbidity of the mental illness, disorder, or condition against the potential risk for adverse outcomes due to drug exposure. Globally, maternal mental health problems are considered as a major public health challenge, which requires a stronger focus on mental health services that will benefit both mother and child.
    [Show full text]
  • Guidance on the Treatment of Antipsychotic Induced Hyperprolactinaemia in Adults
    Guidance on the Treatment of Antipsychotic Induced Hyperprolactinaemia in Adults Version 1 GUIDELINE NO RATIFYING COMMITTEE DRUGS AND THERAPEUTICS GROUP DATE RATIFIED April 2014 DATE AVAILABLE ON INTRANET NEXT REVIEW DATE April 2016 POLICY AUTHORS Nana Tomova, Clinical Pharmacist Dr Richard Whale, Consultant Psychiatrist In association with: Dr Gordon Caldwell, Consultant Physician, WSHT . If you require this document in an alternative format, ie easy read, large text, audio, Braille or a community language, please contact the Pharmacy Team on 01243 623349 (Text Relay calls welcome). Contents Section Title Page Number 1. Introduction 2 2. Causes of Hyperprolactinaemia 2 3. Antipsychotics Associated with 3 Hyperprolactinaemia 4. Effects of Hyperprolactinaemia 4 5. Long-term Complications of Hyperprolactinaemia 4 5.1 Sexual Development in Adolescents 4 5.2 Osteoporosis 4 5.3 Breast Cancer 5 6. Monitoring & Baseline Prolactin Levels 5 7. Management of Hyperprolactinaemia 6 8. Pharmacological Treatment of 7 Hyperprolactinaemia 8.1 Aripiprazole 7 8.2 Dopamine Agonists 8 8.3 Oestrogen and Testosterone 9 8.4 Herbal Remedies 9 9. References 10 1 1.0 Introduction Prolactin is a hormone which is secreted from the lactotroph cells in the anterior pituitary gland under the influence of dopamine, which exerts an inhibitory effect on prolactin secretion1. A reduction in dopaminergic input to the lactotroph cells results in a rapid increase in prolactin secretion. Such a reduction in dopamine can occur through the administration of antipsychotics which act on dopamine receptors (specifically D2) in the tuberoinfundibular pathway of the brain2. The administration of antipsychotic medication is responsible for the high prevalence of hyperprolactinaemia in people with severe mental illness1.
    [Show full text]
  • Neuromodulators for Functional Gastrointestinal Disorders (Disorders of Gutlbrain Interaction): a Rome Foundation Working Team Report Douglas A
    Gastroenterology 2018;154:1140–1171 SPECIAL REPORT Neuromodulators for Functional Gastrointestinal Disorders (Disorders of GutLBrain Interaction): A Rome Foundation Working Team Report Douglas A. Drossman,1,2 Jan Tack,3 Alexander C. Ford,4,5 Eva Szigethy,6 Hans Törnblom,7 and Lukas Van Oudenhove8 1Center for Functional Gastrointestinal and Motility Disorders, University of North Carolina, Chapel Hill, North Carolina; 2Center for Education and Practice of Biopsychosocial Care and Drossman Gastroenterology, Chapel Hill, North Carolina; 3Translational Research Center for Gastrointestinal Disorders, University of Leuven, Leuven, Belgium; 4Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, United Kingdom; 5Leeds Gastroenterology Institute, St James’s University Hospital, Leeds, United Kingdom; 6Departments of Psychiatry and Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania; 7Departments of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; and 8Laboratory for BrainÀGut Axis Studies, Translational Research Center for Gastrointestinal Disorders, University of Leuven, Leuven, Belgium BACKGROUND & AIMS: Central neuromodulators (antide- summary information and guidelines for the use of central pressants, antipsychotics, and other central nervous neuromodulators in the treatment of chronic gastrointestinal systemÀtargeted medications) are increasingly used for treat- symptoms and FGIDs. Further studies are needed to confirm ment
    [Show full text]
  • (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 1: Background and Methods of the Development of Guidelines Konstantinos N
    Copyedited by: oup International Journal of Neuropsychopharmacology (2017) 20(2): 95–97 doi:10.1093/ijnp/pyx002 Editorial EDITORIAL Treatment Guidelines in Bipolar Disorders and the Importance of Proper Clinical Trial Design Mauricio Tohen Department of Psychiatry & Behavioral Sciences, University of New Mexico Health Sciences Center, Albuquerque, New Mexico. Correspondence: Mauricio Tohen, MD, DrPH, MBA, Department of Psychiatry & Behavioral Sciences, University of New Mexico Health Sciences Center, 2400 Tucker Ave, Albuquerque, NM 87131, USA ([email protected]). A working group led by Dr. Konstantinos Fountoulakis developed (http://clinicaltrials.gov and http://www.clinicalstudyresults. the first International College of Neuropsychopharmacology org) as well as web pages of pharmaceutical companies with (CINP) clinical guidelines for the treatment of Bipolar Disorders compounds used in bipolar disorder up to March 25, 2016. in adult patients. Their work is very thoroughly described in The authors provide a critical analysis of the existing treat- four separate papers (parts) included in this issue of the journal. ment grading methods that led them to determine that there The first article is Background and Methods of the Development was no optimal method to grade treatments for bipolar disorder, of Guidelines (Fountoulakis et al., 2017d); part 2 is Review, therefore creating their own grading system. Their methodology Grading of the Evidence, and a Precise Algorithm (Fountoulakis provides 32 different levels of recommendations, starting with et al., 2017c); part 3 is The Clinical Guidelines (Fountoulakis the optimal: “At least 1 positive 2 active arm RCT vs placebo et al., 2017a); and Part 4 is Unmet Needs in the Treatment of exists, plus positive 1 active arm RCTs, and no negative RCTs.” Bipolar Disorder and Recommendations for Future Research Lower level scenarios take into account posthoc reports, meta- (Fountoulakis et al., 2017b).
    [Show full text]
  • Levosulpiride : a Review
    DELHI PSYCHIATRY JOURNAL Vol. 10 No.2 OCTOBER 2007 Drug Review Levosulpiride : A Review Sparsh Gupta, Gobind Rai Garg, Sumita Halder, Krishna Kishore Sharma Department of Pharmacology, University College of Medical Sciences & G.T.B. Hospital, Dilshad Garden, Delhi-110095 Dopamine is a neurotransmitter known to be Mechanism of action involved in the regulation of mood and behavior. Levosulpride is an atypical antipsychotic agent Psychotic illness is thought to be caused due to that blocks the presynaptic dopaminergic D 2 disturbance of neurotransmitters (chiefly dopamine) receptors.1 Like its parent compound, levosulpiride in the brain. Schizophrenia is a psychotic illness shows antagonism at D and D receptors present 3 2 characterized by dopamine over activity in the brain presynaptically as well as postsynaptically in the and so anti dopaminergic drugs are a useful rat striatum or nucleus accumbens2. The preferential component of the therapy for the management of binding of the presynaptic dopamine receptors this disease. decreases the synthesis and release of dopamine at Levosulpiride is the levo enantiomer of low doses whereas it causes postsynaptic D 2 sulpiride. It is a substituted benzamide which is receptor antagonism at higher dose. This receptor meant to be used for several indications: depression, profile of the drug along with its limbic selectivity psychosis, somatoform disorders, emesis and explains its effectiveness in the management of both dyspepsia. It is physically present as a white positive and negative symptoms of schizophrenia.3 crystalline powder with the chemical structure as follows: Pharmacokinetics The parent drug is given in a dose of 400-1800 mg orally daily although a much lower dose is effective for producing antidepressant effect (about 50-300 mg).The plasma t of the drug is about 6-8 1/2 hours.
    [Show full text]
  • Association Between the Use of Antidepressants
    Diabetes Care 1 Hiroyuki Miidera,1 Minori Enomoto,1,2 Association Between the Use of Shingo Kitamura,1 Hisateru Tachimori,3,4 Antidepressants and the Risk of and Kazuo Mishima1,5,6 Type 2 Diabetes Mellitus: A Large, Population-Based Cohort Study in Japan https://doi.org/10.2337/dc19-1175 OBJECTIVE This study aimed to reveal the associations between the risk of new-onset type 2 diabetes mellitus and the duration of antidepressant use and the antidepressant dose, and between antidepressant use after diabetes onset and clinical outcomes. RESEARCH DESIGN AND METHODS In this large-scale retrospective cohort study in Japan, new users of antidepressants (exposure group) and nonusers (nonexposure group), aged 20–79 years, were included between 1 April 2006 and 31 May 2015. Patients with a history of diabetes mellitus or receipt of antidiabetes treatment were excluded. Covariates were adjusted by using propensity score matching; the associations were analyzed between risk of new-onset type 2 diabetes and the duration of antidepressant use/ 1Department of Sleep-Wake Disorders, National dose of antidepressant in the exposure and nonexposure groups by using Cox Institute of Mental Health, National Center of CARDIOVASCULAR AND METABOLIC RISK proportional hazards models. Changes in glycated hemoglobin (HbA1c) level were Neurology and Psychiatry, Tokyo, Japan 2 examined in groups with continuous use, discontinuation, or a reduction in the dose Department of Medical Technology, School of Health Science, Tokyo University of Technology, of antidepressants. Tokyo, Japan 3TranslationalMedicalCenter,NationalCenterof RESULTS Neurology and Psychiatry, Tokyo, Japan Of 90,530 subjects, 45,265 were in both the exposure and the nonexposure group 4Institute for Global Health Policy Research, Bureau after propensity score matching; 5,225 patients (5.8%) developed diabetes.
    [Show full text]